Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (11)

1

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

enthalten in: Current HIV research | 2012

von Bánhegyi, D. | Katlama, C. | da Cunha, C. | +7

2

Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240

enthalten in: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | 2010

von Visser, M. | Baert, L. | Klooster, G. | +8

3

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

enthalten in: Antiviral therapy | 2010

von Dierynck, I. | De Meyer, S. | Lathouwers, E. | +5

4

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

enthalten in: AIDS (London, England) | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

5

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

enthalten in: AIDS (London, England) | 2008

von Ortiz, R. | Dejesus, E. | Khanlou, H. | +9

6

Resistance profile of darunavir : combined 24-week results from the POWER trials

enthalten in: AIDS research and human retroviruses | 2008

von de Meyer, S. | Vangeneugden, T. | van Baelen, B. | +5

7

Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients"

enthalten in: AIDS (London, England) | 2008

von Picchio, G. | De Meyer, S. | de Béthune, M.

CommentOn: AIDS. 2007 May 31;21(9):1210-3. - PMID 17502734

8

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

enthalten in: Antimicrobial agents and chemotherapy | 2005

von De Meyer, S. | Azijn, H. | Surleraux, D. | +5

9

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen : a 14-day proof-of-principle trial

enthalten in: AIDS (London, England) | 2005

von Arastéh, K. | Clumeck, N. | Pozniak, A. | +7

10

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor

enthalten in: Journal of medicinal chemistry | 2005

von Surleraux, D. | Tahri, A. | Verschueren, W. | +12